Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
Küçük Resim Yok
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose. - To define the factors which may be related to brain metastasis (BM) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who developed brain metastases after definitive treatment. Patients and methods. - A total of 208 patients with LA-NSCLC, without BM who received definitive radiotherapy (RT) or RT + chemotherapy (CT) between January 2005 and January 2016 were evaluated retrospectively. Platelet, neutrophil, lymphocyte counts, LDH, CRP, Hb levels, neutrophil-to-lymphocyte radio (NLR), platelet-to-lymphocyte radio (PLR), advanced lung cancer inflammation index (ALI) and FDG-PET/CT parameters (SUVmax of the primary tumor and mediastinal lymph nodes), and patient characteristics were evaluated for brain metastasis free survival (BMFS). Results. - Median follow-up duration was 25 months (range: 3-130 months). Cut-off values for platelet, NLR, PLR, LDH, CRP, and Hb were 290 x 103/mu L, 2.6, 198, 468 IU/L, 2.5 mg/dL, and 11.5 g/d1. We defined each parameter as low or high according to the cut-off values. 56 patients (26.9%) developed brain metastases during follow-up. In univariate analysis, high NLR (P=0.001), PLR (P=0.037), LDH (P = 0.028), CRP (P = 0.002) values, value >= 7.5 for lymph nodes (P = 0.005) and low ALI value (P = 0.002) were poor prognostic factors for BMFS. In multivariate analysis, high NLR (P= 0.022), PLR (P= 0.017), CRP (P= 0.006), stage >= IIIB disease (P< 0.001), multi-stational N2 disease (P= 0.036), adenocarcinoma histology (P< 0.001) and SUVmax value >= 7.5 (P = 0.035) were poor prognostic factors for BMFS. Conclusions. - High NLR, PLR, LDH, CRP values, SUVmax values for lymph nodes, and low ALI which indicates high tumor burden were additional prognostic factors besides stage, histology, and lymph node status. (C) 2020 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
Açıklama
Anahtar Kelimeler
Prophylactic cranial irradiation, Predictive markers, Lung cancer, Non-small cell lung cancer, Prophylactic Cranial Irradiation, To-Lymphocyte Ratio, Prognostic-Significance, Poor Survival, Risk-Factors, Metastases, Inflammation, Platelet
Kaynak
Cancer Radiotherapie
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
25
Sayı
4
